Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q30201
UPID:
HFE_HUMAN
Alternative names:
HLA-H
Alternative UPACC:
Q30201; B2CKL0; O75929; O75930; O75931; Q17RT0; Q96KU5; Q96KU6; Q96KU7; Q96KU8; Q9HC64; Q9HC68; Q9HC70; Q9HC83
Background:
The Hereditary hemochromatosis protein, also known as HLA-H, plays a crucial role in iron metabolism by binding to the transferrin receptor (TFR) and reducing its affinity for iron-loaded transferrin. This protein's function is pivotal in maintaining iron homeostasis in the body.
Therapeutic significance:
HLA-H is implicated in several diseases, including Hemochromatosis 1, Variegate porphyria, and Microvascular complications of diabetes 7. These associations highlight the protein's potential as a target for therapeutic interventions aimed at treating iron overload conditions and their complications.